661 related articles for article (PubMed ID: 11172188)
21. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
22. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
24. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
25. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
26. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.
Learmont JC; Geczy AF; Mills J; Ashton LJ; Raynes-Greenow CH; Garsia RJ; Dyer WB; McIntyre L; Oelrichs RB; Rhodes DI; Deacon NJ; Sullivan JS
N Engl J Med; 1999 Jun; 340(22):1715-22. PubMed ID: 10352163
[TBL] [Abstract][Full Text] [Related]
27. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
[TBL] [Abstract][Full Text] [Related]
28. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
29. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
[TBL] [Abstract][Full Text] [Related]
30. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
Danner SA; Carr A; Leonard JM; Lehman LM; Gudiol F; Gonzales J; Raventos A; Rubio R; Bouza E; Pintado V
N Engl J Med; 1995 Dec; 333(23):1528-33. PubMed ID: 7477167
[TBL] [Abstract][Full Text] [Related]
31. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
Markowitz M; Saag M; Powderly WG; Hurley AM; Hsu A; Valdes JM; Henry D; Sattler F; La Marca A; Leonard JM
N Engl J Med; 1995 Dec; 333(23):1534-9. PubMed ID: 7477168
[TBL] [Abstract][Full Text] [Related]
32. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
[TBL] [Abstract][Full Text] [Related]
33. Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
[TBL] [Abstract][Full Text] [Related]
34. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J; Mayers DL; Hullsiek KH; Collins G; Abrams DI; Reisler RB; Crane LR; Schmetter BS; Dionne TJ; Saldanha JM; Jones MC; Baxter JD;
N Engl J Med; 2003 Aug; 349(9):837-46. PubMed ID: 12944569
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral-drug resistance among patients recently infected with HIV.
Little SJ; Holte S; Routy JP; Daar ES; Markowitz M; Collier AC; Koup RA; Mellors JW; Connick E; Conway B; Kilby M; Wang L; Whitcomb JM; Hellmann NS; Richman DD
N Engl J Med; 2002 Aug; 347(6):385-94. PubMed ID: 12167680
[TBL] [Abstract][Full Text] [Related]
36. Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.
Sarmati L; Montano M; Dori L; Buonomini AR; D'Ettorre G; Vullo V; Andreoni M
New Microbiol; 2004 Apr; 27(2 Suppl 1):95-8. PubMed ID: 15646070
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
[TBL] [Abstract][Full Text] [Related]
38. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.
Pantaleo G; Menzo S; Vaccarezza M; Graziosi C; Cohen OJ; Demarest JF; Montefiori D; Orenstein JM; Fox C; Schrager LK
N Engl J Med; 1995 Jan; 332(4):209-16. PubMed ID: 7808486
[TBL] [Abstract][Full Text] [Related]
39. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.
Barbour JD; Wrin T; Grant RM; Martin JN; Segal MR; Petropoulos CJ; Deeks SG
J Virol; 2002 Nov; 76(21):11104-12. PubMed ID: 12368352
[TBL] [Abstract][Full Text] [Related]
40. Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure.
De Rossi A
New Microbiol; 2004 Apr; 27(2 Suppl 1):45-50. PubMed ID: 15646064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
